These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 15757202

  • 1. Analysis of nm23-H1 protein immunoreactivity in follicular thyroid tumors.
    Ferenc T, Lewiński A, Lange D, Niewiadomska H, Sygut J, Sporny S, Włoch J, Sałacińska-Los E, Kulig A, Jarzab B.
    Pol J Pathol; 2004; 55(4):149-53. PubMed ID: 15757202
    [Abstract] [Full Text] [Related]

  • 2. Analysis of P161NK4A protein expression in follicular thyroid tumors.
    Ferenc T, Lewiński A, Lange D, Niewiadomska H, Sygut J, Sporny S, Jarzab B, Sałacińska-Loś E, Kulig A, Włoch J.
    Pol J Pathol; 2004; 55(4):143-8. PubMed ID: 15757201
    [Abstract] [Full Text] [Related]

  • 3. Analysis of cyclin D1 and retinoblastoma protein immunoreactivity in follicular thyroid tumors.
    Ferenc T, Lewiński A, Lange D, Niewiadomska H, Sygut J, Sporny S, Jarzab B, Satacińska-Los E, Kulig A, Włoch J.
    Pol J Pathol; 2005; 56(1):27-35. PubMed ID: 15921011
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
    Tabriz HM, Adabi Kh, Lashkari A, Heshmat R, Haghpanah V, Larijani B, Tavangar SM.
    Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nm23 protein expression in thyroid neoplasms.
    Royds JA, Silcocks PB, Rees RC, Stephenson TJ.
    Pathologica; 1994 Jun; 86(3):240-3. PubMed ID: 7808792
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preferential reduction of nm23-H1 gene product in metastatic tissues from papillary and follicular carcinomas of the thyroid.
    Arai T, Yamashita T, Urano T, Masunaga A, Itoyama S, Itoh K, Shiku H, Sugawara I.
    Mod Pathol; 1995 Apr; 8(3):252-6. PubMed ID: 7617649
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of MIB-1 immunoreactivity and nucleolar organizer regions in nonneoplastic and neoplastic thyroid lesions.
    Lewy-Trenda I, Bieńkiewicz M.
    Pol J Pathol; 1999 Apr; 50(3):129-38. PubMed ID: 10624114
    [Abstract] [Full Text] [Related]

  • 11. Immunohistochemical analysis of expression of nm23-H1/nucleoside diphosphate kinase in human thyroid carcinomas: lack of correlation between its expression and lymph node metastasis.
    Luo W, Matsuo K, Nagayama Y, Urano T, Furukawa K, Takeshita A, Nakayama T, Yokoyama N, Yamashita S, Izumi M.
    Thyroid; 1993 Apr; 3(2):105-9. PubMed ID: 8396479
    [Abstract] [Full Text] [Related]

  • 12. Retinoblastoma expression in thyroid neoplasms.
    Anwar F, Emond MJ, Schmidt RA, Hwang HC, Bronner MP.
    Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas.
    Kamoshida S, Ogane N, Yasuda M, Muramatsu T, Bessho T, Kajiwara H, Osamura RY.
    Mod Pathol; 2000 Jul; 13(7):736-41. PubMed ID: 10912932
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
    Omar E, Madhavan M, Othman NH.
    Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
    [Abstract] [Full Text] [Related]

  • 15. nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma.
    Zafon C, Obiols G, Castellví J, Tallada N, Galofré P, Gemar E, Mesa J, Simó R.
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3975-80. PubMed ID: 11502841
    [Abstract] [Full Text] [Related]

  • 16. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
    Gustafson KS, LiVolsi VA, Furth EE, Pasha TL, Putt ME, Baloch ZW.
    Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Discovery and validation of protein abundance differences between follicular thyroid neoplasms.
    Netea-Maier RT, Hunsucker SW, Hoevenaars BM, Helmke SM, Slootweg PJ, Hermus AR, Haugen BR, Duncan MW.
    Cancer Res; 2008 Mar 01; 68(5):1572-80. PubMed ID: 18316623
    [Abstract] [Full Text] [Related]

  • 19. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
    Tang QS, Teng XD, Ding W, Zhou J, Yao HT, Ying LX, Xu LM.
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov 01; 40(11):745-8. PubMed ID: 22336157
    [Abstract] [Full Text] [Related]

  • 20. Biological differential diagnosis of follicular thyroid tumor and Hürthle cell tumor on the basis of telomere length and hTERT expression.
    Sugishita Y, Kammori M, Yamada O, Yamazaki K, Ito K, Fukumori T, Yoshikawa K, Yamada T.
    Ann Surg Oncol; 2014 Jul 01; 21(7):2318-25. PubMed ID: 24562933
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.